1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Prevention 1.2.3 Physiotherapy 1.2.4 Immunity Therapy 1.3 Market by Application 1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospitals 1.3.3 Ambulatory Surgical Center 1.3.4 Diagnostic Centers 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2016-2027) 2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Regions 2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Share by Regions (2016-2021) 2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2022-2027) 2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Dynamic 2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends 2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers 2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges 2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue 3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2016-2021) 3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2016-2021) 3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue 3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio 3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2020 3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served 3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service 3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type 4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2016-2021) 4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2022-2027) 5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application 5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2016-2021) 5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027) 6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type 6.2.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) 6.2.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) 6.2.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027) 6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application 6.3.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) 6.3.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) 6.3.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027) 6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country 6.4.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) 6.4.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) 6.4.3 United States 6.4.3 Canada 7 Europe 7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027) 7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type 7.2.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) 7.2.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) 7.2.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027) 7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application 7.3.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) 7.3.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) 7.3.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027) 7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country 7.4.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) 7.4.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027) 8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type 8.2.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027) 8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application 8.3.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027) 8.4 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region 8.4.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027) 9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type 9.2.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) 9.2.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) 9.2.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027) 9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application 9.3.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) 9.3.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) 9.3.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027) 9.4 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country 9.4.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) 9.4.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027) 10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type 10.2.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027) 10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application 10.3.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027) 10.4 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country 10.4.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Achaogen Inc 11.1.1 Achaogen Inc Company Details 11.1.2 Achaogen Inc Business Overview 11.1.3 Achaogen Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.1.4 Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.1.5 Achaogen Inc Recent Development 11.2 Adenium Biotech ApS 11.2.1 Adenium Biotech ApS Company Details 11.2.2 Adenium Biotech ApS Business Overview 11.2.3 Adenium Biotech ApS Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.2.4 Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.2.5 Adenium Biotech ApS Recent Development 11.3 Aridis Pharmaceuticals LLC 11.3.1 Aridis Pharmaceuticals LLC Company Details 11.3.2 Aridis Pharmaceuticals LLC Business Overview 11.3.3 Aridis Pharmaceuticals LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.3.4 Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.3.5 Aridis Pharmaceuticals LLC Recent Development 11.4 AstraZeneca Plc 11.4.1 AstraZeneca Plc Company Details 11.4.2 AstraZeneca Plc Business Overview 11.4.3 AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.4.4 AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.4.5 AstraZeneca Plc Recent Development 11.5 Bayer AG 11.5.1 Bayer AG Company Details 11.5.2 Bayer AG Business Overview 11.5.3 Bayer AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.5.4 Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.5.5 Bayer AG Recent Development 11.6 Cardeas Pharma Corp 11.6.1 Cardeas Pharma Corp Company Details 11.6.2 Cardeas Pharma Corp Business Overview 11.6.3 Cardeas Pharma Corp Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.6.4 Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.6.5 Cardeas Pharma Corp Recent Development 11.7 Destiny Pharma Ltd 11.7.1 Destiny Pharma Ltd Company Details 11.7.2 Destiny Pharma Ltd Business Overview 11.7.3 Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.7.4 Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.7.5 Destiny Pharma Ltd Recent Development 11.8 Dong-A Socio Holdings Co Ltd 11.8.1 Dong-A Socio Holdings Co Ltd Company Details 11.8.2 Dong-A Socio Holdings Co Ltd Business Overview 11.8.3 Dong-A Socio Holdings Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.8.4 Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.8.5 Dong-A Socio Holdings Co Ltd Recent Development 11.9 Lakewood-Amedex Inc 11.9.1 Lakewood-Amedex Inc Company Details 11.9.2 Lakewood-Amedex Inc Business Overview 11.9.3 Lakewood-Amedex Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.9.4 Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.9.5 Lakewood-Amedex Inc Recent Development 11.10 MedImmune LLC 11.10.1 MedImmune LLC Company Details 11.10.2 MedImmune LLC Business Overview 11.10.3 MedImmune LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.10.4 MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.10.5 MedImmune LLC Recent Development 11.11 Meiji Seika Pharma Co Ltd 11.11.1 Meiji Seika Pharma Co Ltd Company Details 11.11.2 Meiji Seika Pharma Co Ltd Business Overview 11.11.3 Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.11.4 Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.11.5 Meiji Seika Pharma Co Ltd Recent Development 11.12 Merck & Co Inc 11.12.1 Merck & Co Inc Company Details 11.12.2 Merck & Co Inc Business Overview 11.12.3 Merck & Co Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.12.4 Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.12.5 Merck & Co Inc Recent Development 11.13 Motif Bio Plc 11.13.1 Motif Bio Plc Company Details 11.13.2 Motif Bio Plc Business Overview 11.13.3 Motif Bio Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.13.4 Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.13.5 Motif Bio Plc Recent Development 11.14 Nabriva Therapeutics AG 11.14.1 Nabriva Therapeutics AG Company Details 11.14.2 Nabriva Therapeutics AG Business Overview 11.14.3 Nabriva Therapeutics AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.14.4 Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.14.5 Nabriva Therapeutics AG Recent Development 11.15 Polyphor Ltd 11.15.1 Polyphor Ltd Company Details 11.15.2 Polyphor Ltd Business Overview 11.15.3 Polyphor Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.15.4 Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.15.5 Polyphor Ltd Recent Development 11.16 Shionogi & Co Ltd 11.16.1 Shionogi & Co Ltd Company Details 11.16.2 Shionogi & Co Ltd Business Overview 11.16.3 Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.16.4 Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.16.5 Shionogi & Co Ltd Recent Development 11.17 Tetraphase Pharmaceuticals Inc 11.17.1 Tetraphase Pharmaceuticals Inc Company Details 11.17.2 Tetraphase Pharmaceuticals Inc Business Overview 11.17.3 Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.17.4 Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.17.5 Tetraphase Pharmaceuticals Inc Recent Development 11.18 The Medicines Company 11.18.1 The Medicines Company Company Details 11.18.2 The Medicines Company Business Overview 11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.18.5 The Medicines Company Recent Development 11.18 Theravance Biopharma Inc .1 Theravance Biopharma Inc Company Details .2 Theravance Biopharma Inc Business Overview .3 Theravance Biopharma Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction .4 Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) .5 Theravance Biopharma Inc Recent Development 11.20 Wockhardt Ltd 11.20.1 Wockhardt Ltd Company Details 11.20.2 Wockhardt Ltd Business Overview 11.20.3 Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.20.4 Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.20.5 Wockhardt Ltd Recent Development 11.21 Zavante Therapeutics Inc 11.21.1 Zavante Therapeutics Inc Company Details 11.21.2 Zavante Therapeutics Inc Business Overview 11.21.3 Zavante Therapeutics Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction 11.21.4 Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) 11.21.5 Zavante Therapeutics Inc Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Prevention Table 3. Key Players of Physiotherapy Table 4. Key Players of Immunity Therapy Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (2016-2021) & (US$ Million) Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2016-2021) Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2022-2027) Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2016-2021) & (US$ Million) Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2016-2021) Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2020) Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2020 Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2016-2021) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service Table 22. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2016-2021) Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million) Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million) Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million) Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2016-2021) Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million) Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million) Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 34. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 35. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 36. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 37. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 38. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 39. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 40. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 41. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 42. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 43. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 44. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 45. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 46. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 47. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 48. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2016-2021) & (US$ Million) Table 49. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2022-2027) & (US$ Million) Table 50. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 51. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 52. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 53. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 54. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 55. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 56. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 57. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 58. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 59. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 60. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 61. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 62. Achaogen Inc Company Details Table 63. Achaogen Inc Business Overview Table 64. Achaogen Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 65. Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 66. Achaogen Inc Recent Development Table 67. Adenium Biotech ApS Company Details Table 68. Adenium Biotech ApS Business Overview Table 69. Adenium Biotech ApS Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 70. Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 71. Adenium Biotech ApS Recent Development Table 72. Aridis Pharmaceuticals LLC Company Details Table 73. Aridis Pharmaceuticals LLC Business Overview Table 74. Aridis Pharmaceuticals LLC Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 75. Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 76. Aridis Pharmaceuticals LLC Recent Development Table 77. AstraZeneca Plc Company Details Table 78. AstraZeneca Plc Business Overview Table 79. AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 80. AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 81. AstraZeneca Plc Recent Development Table 82. Bayer AG Company Details Table 83. Bayer AG Business Overview Table 84. Bayer AG Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 85. Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 86. Bayer AG Recent Development Table 87. Cardeas Pharma Corp Company Details Table 88. Cardeas Pharma Corp Business Overview Table 89. Cardeas Pharma Corp Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 90. Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 91. Cardeas Pharma Corp Recent Development Table 92. Destiny Pharma Ltd Company Details Table 93. Destiny Pharma Ltd Business Overview Table 94. Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 95. Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 96. Destiny Pharma Ltd Recent Development Table 97. Dong-A Socio Holdings Co Ltd Company Details Table 98. Dong-A Socio Holdings Co Ltd Business Overview Table 99. Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 100. Dong-A Socio Holdings Co Ltd Recent Development Table 101. Lakewood-Amedex Inc Company Details Table 102. Lakewood-Amedex Inc Business Overview Table 103. Lakewood-Amedex Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 104. Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 105. Lakewood-Amedex Inc Recent Development Table 106. MedImmune LLC Company Details Table 107. MedImmune LLC Business Overview Table 108. MedImmune LLC Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 109. MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 110. MedImmune LLC Recent Development Table 111. Meiji Seika Pharma Co Ltd Company Details Table 112. Meiji Seika Pharma Co Ltd Business Overview Table 113. Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 114. Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 115. Meiji Seika Pharma Co Ltd Recent Development Table 116. Merck & Co Inc Company Details Table 117. Merck & Co Inc Business Overview Table 118. Merck & Co Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 119. Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 120. Merck & Co Inc Recent Development Table 121. Motif Bio Plc Company Details Table 122. Motif Bio Plc Business Overview Table 123. Motif Bio Plc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 124. Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 125. Motif Bio Plc Recent Development Table 126. Nabriva Therapeutics AG Company Details Table 127. Nabriva Therapeutics AG Business Overview Table 128. Nabriva Therapeutics AG Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 129. Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 130. Nabriva Therapeutics AG Recent Development Table 131. Polyphor Ltd Company Details Table 132. Polyphor Ltd Business Overview Table 133. Polyphor Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 134. Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 135. Polyphor Ltd Recent Development Table 136. Shionogi & Co Ltd Company Details Table 137. Shionogi & Co Ltd Business Overview Table 138. Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 139. Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 140. Shionogi & Co Ltd Recent Development Table 141. Tetraphase Pharmaceuticals Inc Company Details Table 142. Tetraphase Pharmaceuticals Inc Business Overview Table 143. Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 144. Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 145. Tetraphase Pharmaceuticals Inc Recent Development Table 146. The Medicines Company Company Details Table 147. The Medicines Company Business Overview Table 148. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 149. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 150. The Medicines Company Recent Development Table 151. Theravance Biopharma Inc Company Details Table 152. Theravance Biopharma Inc Business Overview Table 153. Theravance Biopharma Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 154. Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 155. Theravance Biopharma Inc Recent Development Table 156. Wockhardt Ltd Company Details Table 157. Wockhardt Ltd Business Overview Table 158. Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 159. Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 160. Wockhardt Ltd Recent Development Table 161. Zavante Therapeutics Inc Company Details Table 162. Zavante Therapeutics Inc Business Overview Table 163. Zavante Therapeutics Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product Table 164. Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million) Table 165. Zavante Therapeutics Inc Recent Development Table 166. Research Programs/Design for This Report Table 167. Key Data Information from Secondary Sources Table 168. Key Data Information from Primary Sources List of Figures Figure 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2020 VS 2027 Figure 2. Prevention Features Figure 3. Physiotherapy Features Figure 4. Immunity Therapy Features Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2020 VS 2027 Figure 6. Hospitals Case Studies Figure 7. Ambulatory Surgical Center Case Studies Figure 8. Diagnostic Centers Case Studies Figure 9. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered Figure 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions: 2020 VS 2027 Figure 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2022-2027) Figure 14. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2020 Figure 15. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2020 Figure 16. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2020 Figure 17. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2016-2021) Figure 18. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2022-2027) Figure 19. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 20. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027) Figure 21. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027) Figure 22. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027) Figure 23. United States Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027) Figure 27. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027) Figure 28. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027) Figure 29. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Nordic Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027) Figure 37. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027) Figure 38. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2016-2027) Figure 39. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Australia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027) Figure 47. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027) Figure 48. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027) Figure 49. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027) Figure 53. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027) Figure 54. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027) Figure 55. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. UAE Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Achaogen Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 59. Adenium Biotech ApS Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 60. Aridis Pharmaceuticals LLC Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 61. AstraZeneca Plc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 62. Bayer AG Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 63. Cardeas Pharma Corp Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 64. Destiny Pharma Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 65. Dong-A Socio Holdings Co Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 66. Lakewood-Amedex Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 67. MedImmune LLC Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 68. Meiji Seika Pharma Co Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 69. Merck & Co Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 70. Motif Bio Plc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 71. Nabriva Therapeutics AG Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 72. Polyphor Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 73. Shionogi & Co Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 74. Tetraphase Pharmaceuticals Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 75. The Medicines Company Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 76. Theravance Biopharma Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 77. Wockhardt Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 78. Zavante Therapeutics Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) Figure 79. Bottom-up and Top-down Approaches for This Report Figure 80. Data Triangulation Figure 81. Key Executives Interviewed

Achaogen Inc Adenium Biotech ApS Aridis Pharmaceuticals LLC AstraZeneca Plc Bayer AG Cardeas Pharma Corp Destiny Pharma Ltd Dong-A Socio Holdings Co Ltd Lakewood-Amedex Inc MedImmune LLC Meiji Seika Pharma Co Ltd Merck & Co Inc Motif Bio Plc Nabriva Therapeutics AG Polyphor Ltd Shionogi & Co Ltd Tetraphase Pharmaceuticals Inc The Medicines Company Theravance Biopharma Inc Wockhardt Ltd Zavante Therapeutics Inc